Uri Lopatin - Assembly Biosciences Insider

ASMB -- USA Stock  

USD 36.10  0.69  1.88%

  President
Dr. Uri Lopatin, M.D. is the Vice President Research Development, Chief Medical Officer of tAssembly Biosciences Inc. At Assembly Pharmaceuticals, he was Chief Medical Officer and Vice President Research and Development, a position he held since October, 2012. Prior to that, he was a Senior Director for Clinical and Translational ResearchLiver Disease at Gilead Sciences from October, 2010 to September, 2012, a Translational Medical Leader at Roche from May, 2008 to September, 2010. Dr. Lopatin has designed and coordinated preclinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. Dr. Lopatin received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School, where he was awarded the Stanley S. Bergen medal of excellence.
Age: 45  President Since 2014  Ph.D    
317-210-9311  http://www.assemblybio.com
Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of excellence. He holds a BA in biology from Cornell University, where he graduated cum laude with distinction in all subjects.

Uri Lopatin Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (32.32) % which means that it has lost $32.32 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.11) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 11 records

PRESIDENT Since

Erik CheliusEndocyte
2018
Theodore AshburnDicerna Pharmaceuticals
2014
David MozleyEndocyte
2015
David JohnsonDynavax Technologies Corporatio
2014
Kevin LaliberteDova Pharmaceuticals
2017
Michael OstrachDynavax Technologies Corporatio
2016
Bradford MiddlekauffEdge Therapeutics
2015
Robert JanssenDynavax Technologies Corporatio
2018
Alyssa WyantEdge Therapeutics
2017
Michael BrinkleyEndocyte
2013
Katherine ParkerEndocyte
2015

Entity Summary

Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 89 people.Assembly Biosciences (ASMB) is traded on BATS Exchange in USA. It is located in NEW YORK U.S.A and employs 89 people. Assembly Biosciences was previously known as ASSEMBLY BIOSCIENCES INC and was traded on BATS Exchange under the symbol VTUS. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Assembly Biosciences Leadership Team

Uri Lopatin, Vice President - Research & Development, Chief Medical Officer
Helen Kim, Independent Director
Myron Holubiak, Independent Director
Lee Arnold, Chief Scientific Officer
Jacqueline Papkoff, Senior Vice President Chief Scientific Officer Microbiome
Anthony Altig, Independent Director
Richard Colonno, Chief Scientific Officer
Graham Cooper, CFO, COO and Principal Financial Officer and Principal Accounting Officer
William Ringo, Non-Executive Chairman of the Board
Susan Mahony, Director
Richard DiMarchi, Director
Miguel Barbosa, Chief Scientific Officer, Head of Microbiome Program
Thomas Rollins, Chief Development Officer
Mark Auerbach, Independent Director
Derek Small, Co-Founder, CEO and President and Director
Alan Lewis, Director
David Barrett, CFO, COO

Stock Performance Indicators

Current Sentiment - ASMB

Assembly Biosciences Investor Sentiment

Most of Macroaxis users are presently bullish on Assembly Biosciences. What is your sentiment towards investing in Assembly Biosciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Assembly Biosciences Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Assembly Biosciences and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try CEO Directory module to screen ceos from public companies around the world.
Search macroaxis.com